Reach Us +1-217-403-9671
Pharmacovigilance System In India: Scope And Limitations | 7424
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Pharmacovigilance system in India: Scope and limitations

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Diwakar Yadav, Prof. Dr. B. P. Nagori and Vipin Mathur

Posters: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.007

Use of medicinal products is not completely safe and sometimes it may lead to harmful effects in the body known as the Adverse Drug Reactions (ADRs). Pharmacovigilance is a system that improves the safe and rational use of medicines. WHO defines Pharmacovigilance as ?the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug related problems?. The basic aims of Pharmacovigilance are improvement in patient care and safety, to contribute in the assessment of benefit, harm, effectiveness and risk of medicines and to promote education and clinical training on rational and safe use of medicines. India is becoming a major hub for clinical trials but the Pharmacovigilance system in India is still in its infancy. Although ?Pharmacovigilance programme of India for assuring drug safety? was launched in 2004 but it has yet not been implemented effectively. Discrepancies exist between the provisions of Schedule Y and Central Drugs Standard Control Organization (CDSCO) guidelines for ADRs reporting. Need therefore exists to critically review the present Pharmacovigilance system in the country. This paper presents an overview of the current regulatory framework for Pharmacovigilance in India and discusses its limitations. Further, recommendations are provided to formulate a comprehensive and vibrant Pharmacovigilance system in India to protect country?s population from the potential harm of the new drugs.
Mr. Diwakar Yadav is presently pursuing M. Pharmacy in Pharmaceutical Management & Regulatory Affairs branch at Lachoo Memorial College of Science & Technology, Pharmacy Wing, Jodhpur, India.